N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (Synonyms: DANA) |
| رقم الكتالوجGC44298 |
N-acetyl-2،3-dehydro-2-Deoxyneuraminic Acid (Neu5Ac2en) هو مثبط قوي للنيورامينيداز (سياليديز).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 24967-27-9
Sample solution is provided at 25 µL, 10mM.
N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid is an effective mammal sialidase (neuraminidase) inhibitor[1]. N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid can also inhibite Clostridium Perfringens sialidase, which has the IC50 value of 4μM[2]. N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid is sialidase transition state analog, and has been used as an important probe for structural and mechanistic studies of sialidases[3].
N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (50μM; 3 days) decreased the growing number of myotube induced by lactate (15mM; 3-5 days) treatment in C2C12 cells[4]. N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (1mM; 180min) increased glutamate release from rat hippocampus neurons[5].
N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (70-2100μmol/kg; intravenous injection; 30min) attenuated the mice blood glucose level after injection with glucose (2g/kg; i.p. ;120min) in a concentration-dependent manner[6]. N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (10mg/kg; i.p. ; 20 days) and Tamiflu (10mg/kg; i.p. ; 20 days) treatments decreased the bleomycin (3U/kg; oropharyngeal aspiration; 1 day) induced lung fibrosis in mice[7].
References:
[1] MAGESH S, MORIYA S, SUZUKI T, et al. Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: selective inhibitors of lysosomal sialidase (NEU1) [J]. Bioorg Med Chem Lett, 2008, 18(2): 532-7.
[2] HUNT M E, BROWN D R. Role of sialidase in Mycoplasma alligatoris-induced pulmonary fibroblast apoptosis [J]. Vet Microbiol, 2007, 121(1-2): 73-82.
[3] XIAO A, LI Y, LI X, et al. Sialidase-catalyzed one-pot multienzyme (OPME) synthesis of sialidase transition-state analogue inhibitors [J]. ACS Catal, 2018, 8(1): 43-7.
[4] DAI W, WU G, LIU K, et al. Lactate promotes myogenesis via activating H3K9 lactylation-dependent up-regulation of Neu2 expression [J]. J Cachexia Sarcopenia Muscle, 2023, 14(6): 2851-65.
[5] MINAMI A, ISHII A, SHIMBA S, et al. Down-regulation of glutamate release from hippocampal neurons by sialidase [J]. J Biochem, 2018, 163(4): 273-80.
[6] MINAMI A, FUJITA Y, SHIMBA S, et al. The sialidase inhibitor 2,3-dehydro-2-deoxy-N-acetylneuraminic acid is a glucose-dependent potentiator of insulin secretion [J]. Sci Rep, 2020, 10(1): 5198.
[7] KARHADKAR T R, PILLING D, COX N, et al. Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model [J]. Sci Rep, 2017, 7(1): 15069.
| Cell experiment [1]: | |
|
Cell lines |
Mouse myoblast C2C12 cells |
|
Preparation Method |
Mouse myoblast C2C12 cells were grown in incubators at 37℃, 5% CO2. Proliferating cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium added with 1% penicillin-streptomycin and 10% fetal bovine serum. After C2C12 cells grown to 80-90% confluence, cells were cultured in Dulbecco’s modified Eagle’s medium with 1% penicillin-streptomycin and 2% horse serum for myogenic differentiation. |
|
Reaction Conditions |
50μM; 3 days |
|
Applications |
N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid decreased the growing number of myotube induced by lactate treatment in C2C12 cells. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6J mice |
|
Preparation Method |
The mice were housed under standard laboratory conditions (23±1℃, 55±5% humidity) and had access to tap water and diet ad libitum. The lights were automatically turned on at 8:00 and turned off at 20:00. To investigate the effect of N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid on insulin secretion under the fasting condition, N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (70μmol-2100μmol/kg; intravenous injection; 30min) and glucose (2g/kg; i.p. ;120min) were administered by intravenous injection and intraperitoneal injection, respectively, after 24 hour fasting. Blood was sampled before (0min) and at 30min after administration. |
|
Dosage form |
70-2100μmol/kg; intravenous injection; 30min |
|
Applications |
N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid attenuated the mice blood glucose level after injection with glucose in a concentration-dependent manner. |
|
References: |
|
| Cas No. | 24967-27-9 | SDF | |
| المرادفات | DANA | ||
| Canonical SMILES | OC(C1=C[C@H](O)[C@@H](NC(C)=O)[C@@]([C@H](O)[C@H](O)CO)([H])O1)=O | ||
| Formula | C11H17NO8 | M.Wt | 291.3 |
| الذوبان | DMF: 0.1 mg/ml,DMSO: 1 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4329 mL | 17.1644 mL | 34.3289 mL |
| 5 mM | 686.6 μL | 3.4329 mL | 6.8658 mL |
| 10 mM | 343.3 μL | 1.7164 mL | 3.4329 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *